Company: IMNN
Filing Date: 2025-04-04
Form Type: S-1
Source: 0001641172-25-002783
Chunk: 21

Company: Imunon, Inc.
Filing Date: 2025-04-04
Form: S-1
Chunk 21
---
 that the number of shares of Common Stock offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated Placement Agent fees and estimated offering expenses payable by us and assuming no exercise of common warrants or sale of pre-funded warrants. An increase (decrease) of 1,000,000 in the number of shares of Common Stock and accompanying common warrants offered by us would increase (decrease) the as adjusted amount of additional paid-in capital, total stockholders’ equity and total capitalization by approximately $0.9 million ($0.9 million), assuming no change in the public offering price per share of Common Stock and accompanying common warrant, and after deducting estimated Placement Agent fees and estimated offering expenses payable by us.

(1) As adjusted reflects the number of shares of our Common Stock that will be outstanding immediately after this offering and is based on 14,500,685 shares outstanding as of December 31, 2024 and excludes the following:

| ● | 1,645,873                                                                                                                             
 shares of Common Stock issuable upon the exercise of outstanding stock options as of December 31, 2024, having a weighted average     
 exercise price of $1.95 per share;                                                                                                    |
| ● | 39,700                                                                                                                                
 shares of Common Stock issuable upon the vesting of Common Stock awards as of December 31, 2024, having a weighted average grant      
 date fair value of $0.99 per share;                                                                                                   |
| ● | 5,155,060                                                                                                                             
 shares of Common Stock issuable upon the exercise of outstanding warrants as of December 31, 2024, having a weighted average exercise 
 price of $2.51 per share; and                                                                                                         |
| ● | 420,000                                                                                                                               
 shares of Common Stock reserved for future issuance pursuant to our existing stock incentive plan.                                    |

The information discussed above is illustrative only and will adjust based on the actual public offering price and other terms of this offering determined at pricing.

| 10 |

<div align='center'>DILUTION</div>

If you purchase securities in this offering, assuming no sale of any pre-funded warrants and no exercise of the common warrants issued in connection with this offering, your ownership interest will be immediately diluted to the extent of the difference between the combined public offering price per share of our Common Stock and accompanying warrant in this offering and the as adjusted net tangible book value per share of our Common Stock immediately after giving